Epigenetic heterogeneity in breast tumours informs diagnosis and prognosis

Researchers have identified specific epigenetic signatures in breast cancer cells that help distinguish between tumor subtypes and predict patient prognosis. The study suggests that analyzing these markers in blood could lead to more effective early diagnosis and personalized treatment strategies.
Why it matters
This research offers a potential breakthrough in 'liquid biopsy' technology, which could significantly improve early detection and survival rates for breast cancer patients.
Breast cancer, the most diagnosed cancer among women, is stratified by gene expression patterns into luminal and basal-like subtypes, and the latter is associated with worse prognosis 1 , 2 , 3 . Recent advances in single-cell technologies have underscored the presence of intratumour heterogeneity, which poses substantial challenges in cancer treatment and achieving long-term disease-free survival 4 , 5 , 6 , 7 . Here we extensively profile epigenetic heterogeneity in a cohort of treatment-naive human luminal tumours, which were obtained directly after surgical resection. By applying a single-cell epigenetic approach based on cytometry by time-of-flight, we identify a recurrent subpopulation of basal-like cells in luminal tumours with a conserved epigenetic signature across patients. These basal-like cells, also identified by deconvolution of whole-genome DNA methylation patterns, are characterized by high expression of aggressive oncogenic traits and downregulation of hormone receptor signalling.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in